In this issue:
Noninferior survival with sentinel vs axillary dissection
20-year recurrence risks in breast cancer
De-escalation strategies in HER2+ early breast cancer
Canakinumab lowers risk of lung cancer
Durvalumab improves PFS in stage III NSCLC
Alectinib vs crizotinib in untreated ALK+ NSCLC
Evidence in support of blood testing for EGFR mutation
CAP-B maintenance covers all mCRC mutational subgroups
non-V600EBRAF-mutated colorectal tumours: excellent prognosis
Consider tumour sidedness in RAS wt mCRC
Please login below to download this issue (PDF)